<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714530</url>
  </required_header>
  <id_info>
    <org_study_id>ThoRaT</org_study_id>
    <nct_id>NCT02714530</nct_id>
  </id_info>
  <brief_title>Thoracal Radiotherapy and Tarceva</brief_title>
  <acronym>ThoRaT</acronym>
  <official_title>Concomitant Radiotherapy and Erlotinib in Advanced Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if erlotinib given orally along with concurrent
      palliative irradiation to lung cancer improves local control compared to those treated with
      radiotherapy alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endpoints:

      Primary:

        -  To determine if erlotinib given orally along with concurrent external beam radiation
           therapy, prolongs local tumour control as determined by CT evaluation compared to
           treatment with external beam radiation therapy alone

      Secondary:

        -  To confirm the safety profile of erlotinib along with concurrent external beam radiation
           therapy.

        -  To evaluate if erlotinib along with concurrent external beam radiation therapy, improve
           quality of life as assessed with the EORTC QLQ-C30 and the EORTC QLQ-LC13.

        -  To evaluate if PET-CT examination can be used to predict response to treatment.

        -  To evaluate overall survival in the different groups

      Trial Design: Open multicenter two-armed randomized phase II trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with progression in radiation field among patients treated with erlotinib combined with radiotherapy compared to radiotherapy alone</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate local control by radiological evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events grade &gt;3 as Assessed by CTCAE v4.0</measure>
    <time_frame>1 year</time_frame>
    <description>To confirm the safety profile of erlotinib along with concurrent external beam radiation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival will be measured</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate overall survival in the different groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy combined with erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard treatment 3 Gy x 10 to lung tumor and mediastinal lymph nodes and erlotinib given concomitantly, 150 mg p.o. daily from the day before radiation, until the last day of radiation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy 3 Gy x 10 alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Tarceva daily during radiotherapy course</description>
    <arm_group_label>Radiotherapy combined with erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Radiotherapy</description>
    <arm_group_label>Radiotherapy combined with erlotinib</arm_group_label>
    <arm_group_label>Radiotherapy alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Histological or cytological verified NSCLC

          -  Palliative radiotherapy to thorax indicated

          -  ECOG Performance status 0-2

          -  Fertile patients must use contraception

          -  Signed informed consent

          -  Ability to understand and fill in QoL questionnaires

          -  Capability to take per os medication

          -  Serum bilirubin &lt; 2 times upper limit of normal (ULN)

          -  AST and ALT &lt; 2 times ULN (&lt; 5 times ULN if liver metastases are present)

          -  Creatinine &lt; 5 times ULN

        Exclusion Criteria:

          -  Pregnancy or nursing

          -  Other prior or concurrent malignant disease likely to interfere with study treatment
             or comparisons

          -  No evidence of other significant laboratory finding or concurrent uncontrolled medical
             illness, that in the opinion of the investigator, would interfere with study treatment
             or results comparison or render the patient at high risk for treatment complications

          -  No prior radiotherapy to the same organ / place

          -  No concurrent treatment with other experimental drugs

          -  Known brain metastases in need of radiotherapy

          -  Known hypersensitivity to erlotinib or other substances in the erlotinib tablets.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Åslaug Helland, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Åslaug Helland, Md PhD</last_name>
    <email>ahelland@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Odd Brustugun, MD PhD</last_name>
    <email>otb@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <state>International/Other</state>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Åslaug Helland, MD PhD</last_name>
      <phone>95940863</phone>
      <email>ahelland@medisin.uio.no</email>
    </contact>
    <contact_backup>
      <last_name>Tina Traa</last_name>
      <phone>+22934000</phone>
      <email>tina.traa@ous-hf.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7010</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjørn Henning Grønberg, MD PhD</last_name>
      <email>bjorn.h.gronberg@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Åslaug Helland</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publish results</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

